Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chronic renal failure patients requiring hemodialysis and requiring r-HuEPO to maintain adequate hematocrit levels
- Serum ferritin level > 200 micrograms/L and transferrin saturation > 15%
- Serum erythropoietin level less than 500 mu/ml (when off r-HuEPO)
- Prior therapy with r-HuEPO
- An adequate program of dialysis established
- Informed consent signed
Exclusion Criteria:
- Adocumented cause of anemia other than chronic renal disease
- Symptoms of unstable coronary artery disease
- Poorly controled hypertension
- Known seizure disorder
- Other active inflammatory or infective disorders
- Other disorders that may diminish the response of the bone marrow to r-HuEPO
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 0800
r-HuEPO administered at 0800 hrs
|
r-HuEPO 50 U/kg s.c.
three times per week.
The dose is rounded to the nearest 2000 unites.
|
|
Active Comparator: 1500
r-HuEPO administered at 1500 hrs
|
r-HuEPO 50 U/kg s.c.
three times per week.
The dose is rounded to the nearest 2000 unites.
|
|
Active Comparator: 2200
r-HuEPO administered at 2200 hrs
|
r-HuEPO 50 U/kg s.c.
three times per week.
The dose is rounded to the nearest 2000 unites.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Time for hematocrit to rise
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Georg Bjarnason, MD, FRCPC, Sunnybrook Health Sciences Centre
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 022-1994
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.